The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma

Neuroprotective therapies which focus on factors leading to retinal ganglion cells (RGCs) degeneration have been drawing more and more attention. The beneficial effects of nerve growth factor (NGF) on the glaucoma have been recently suggested, but its effects on eye tissue are complex and controvers...

Full description

Bibliographic Details
Main Authors:	Wang, Haitao, Wang, Rikang, Thrimawithana, Thilini, Little, Peter J., Xu, Jiangping, Feng, Zhong-Ping, Zheng, Wenhua
Format:	Online
Language:	English
Published:	Hindawi Publishing Corporation 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164261/

id	pubmed-4164261
recordtype	oai_dc
spelling	pubmed-41642612014-09-23 The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma Wang, Haitao Wang, Rikang Thrimawithana, Thilini Little, Peter J. Xu, Jiangping Feng, Zhong-Ping Zheng, Wenhua Review Article Neuroprotective therapies which focus on factors leading to retinal ganglion cells (RGCs) degeneration have been drawing more and more attention. The beneficial effects of nerve growth factor (NGF) on the glaucoma have been recently suggested, but its effects on eye tissue are complex and controversial in various studies. Recent clinical trials of systemically and topically administrated NGF demonstrate that NGF is effective in treating several ocular diseases, including glaucoma. NGF has two receptors named high affinity NGF tyrosine kinase receptor TrkA and low affinity receptor p75NTR. Both receptors exist in cells in retina like RGC (expressing TrkA) and glia cells (expressing p75NTR). NGF functions by binding to TrkA or p75NTR alone or both together. The binding of NGF to TrkA alone in RGC promotes RGC's survival and proliferation through activation of TrkA and several prosurvival pathways. In contrast, the binding of NGF to p75NTR leads to apoptosis although it also promotes survival in some cases. Binding of NGF to both TrkA and p75NTR at the same time leads to survival in which p75NTR functions as a TrkA helping receptor. This review discusses the current understanding of the NGF signaling in retina and the therapeutic implications in the treatment of glaucoma. Hindawi Publishing Corporation 2014 2014-08-31 /pmc/articles/PMC4164261/ /pubmed/25250333 http://dx.doi.org/10.1155/2014/759473 Text en Copyright © 2014 Haitao Wang et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Wang, Haitao Wang, Rikang Thrimawithana, Thilini Little, Peter J. Xu, Jiangping Feng, Zhong-Ping Zheng, Wenhua
spellingShingle	Wang, Haitao Wang, Rikang Thrimawithana, Thilini Little, Peter J. Xu, Jiangping Feng, Zhong-Ping Zheng, Wenhua The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma
author_facet	Wang, Haitao Wang, Rikang Thrimawithana, Thilini Little, Peter J. Xu, Jiangping Feng, Zhong-Ping Zheng, Wenhua
author_sort	Wang, Haitao
title	The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma
title_short	The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma
title_full	The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma
title_fullStr	The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma
title_full_unstemmed	The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma
title_sort	nerve growth factor signaling and its potential as therapeutic target for glaucoma
description	Neuroprotective therapies which focus on factors leading to retinal ganglion cells (RGCs) degeneration have been drawing more and more attention. The beneficial effects of nerve growth factor (NGF) on the glaucoma have been recently suggested, but its effects on eye tissue are complex and controversial in various studies. Recent clinical trials of systemically and topically administrated NGF demonstrate that NGF is effective in treating several ocular diseases, including glaucoma. NGF has two receptors named high affinity NGF tyrosine kinase receptor TrkA and low affinity receptor p75NTR. Both receptors exist in cells in retina like RGC (expressing TrkA) and glia cells (expressing p75NTR). NGF functions by binding to TrkA or p75NTR alone or both together. The binding of NGF to TrkA alone in RGC promotes RGC's survival and proliferation through activation of TrkA and several prosurvival pathways. In contrast, the binding of NGF to p75NTR leads to apoptosis although it also promotes survival in some cases. Binding of NGF to both TrkA and p75NTR at the same time leads to survival in which p75NTR functions as a TrkA helping receptor. This review discusses the current understanding of the NGF signaling in retina and the therapeutic implications in the treatment of glaucoma.
publisher	Hindawi Publishing Corporation
publishDate	2014
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164261/
_version_	1613133926286491648

The Nerve Growth Factor Signaling and Its Potential as Therapeutic Target for Glaucoma

Similar Items